Building a Tool to Predict Liver Cancer Risk in Chronic Hepatitis B
Builds a model to predict liver cancer risk in adults with hepatitis B.
Plain-language title generated from the registry record
Registry title: HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Friendship Hospital
- Trial code
- NCT07780357
- Record updated
- 28 August 2026
- Original description
The investigators propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis/cirrhosis patients, using multimodal data encompassing longitudinal clinical data, serum glycomics profiles, and liver biopsy histopathological images.Read full original descriptionShow less
Development and Application of an HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
The investigators propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis/cirrhosis patients, using multimodal data encompassing longitudinal clinical data, serum glycomics profiles, and liver biopsy histopathological images.
Inclusion: Aged ≥18 years, both sexes eligible; Diagnosed with hepatitis B-related liver fibrosis or cirrhosis based on clinical assessment or liver histopathology; Undergoing antiviral treatment; Follow-up duration between 0.5- 5 years; Availability of baseline data and at least two longitudinal follow-up visits; Clinical outcomes during the follow-up period are traceable.
Exclusion: Diagnosis of Hepatocellular carcinoma (HCC) or liver transplantation at baseline or within 6 months after baseline/enrollment; Coexisting other chronic liver diseases, such as genetic/metabolic liver diseases, drug-induced liver injury, or severe steatotic liver disease; Coexisting other malignancies (except those considered cured).